SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδ signalling-mediated alternative activation of macrophages
Zhi Li(Dalian Medical University), Jianping Gong(University of Electronic Science and Technology of China), Xiwen Zhu(Dalian Medical University), He Li(Hubei University of Medicine), Zhibo Zhao, Wei Zhu(Ministry of Education of the People's Republic of China), Panpan Feng(Qilu Hospital of Shandong University)
Cited by 66
Related Papers
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168